Physician profile
Alan Fligiel
NPI 1285681486
$851.83
in general payments reported to CMS, 2019-2025
16 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $49.71 · 2021: $243 · 2022: $110 · 2023: $166 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $320.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $178.13 | 2021-2025 | |
| Janssen Biotech, INC. | $152.13 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $143.15 | 2023 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $90.02 | 2019-2022 | |
| Abbvie INC. | $59.83 | 2019-2022 | |
| Pfizer INC. | $50.12 | 2021 | |
| Ucb, INC. | $23.28 | 2019 | |
| Vyne Pharmaceuticals INC. | $23.28 | 2021 | |
| Biofrontera INC. | $22.17 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.78 | 2020 | |
| Chiesi USA, INC. | $17.07 | 2025 | Filsuvez |
| Lilly USA, LLC | $16.64 | 2019 | |
| Leo Pharma INC. | $15.54 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.30 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.86 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Fligiel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.